Non-founder total target cash compensation increased 3.3% at private life science companies in 2015.
References
Rychlik, B. Nat. Biotechnol. 33, 313–316 (2015). Medline
Rychlik, B. Nat. Biotechnol. 32, 393–395 (2014). Medline
Wasserman, N. The Founder's Dilemmas: Anticipating and Avoiding the Pitfalls That Can Sink a Startup (Princeton Univ. Press, 2012).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Rychlik, B. Compensation inflation remains consistent at private life science companies. Nat Biotechnol 34, 667–670 (2016). https://doi.org/10.1038/nbt.3604
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.3604
- Springer Nature America, Inc.
This article is cited by
-
As life sciences sector's positive momentum continues, so do executive compensation levels
Nature Biotechnology (2018)
-
Continuous positive compensation trends indicate a healthy private life sciences sector
Nature Biotechnology (2017)